Visceral leishmaniasis | Since 2016
|Duke University, Durham, USA; Haverford College, USA; Imperial College, London, UK; Indian Institute of Chemical Technology (IICT), Hyderabad, India; Indian Institute of Technology, Gandhinagar, India; Miami University, USA; Northeastern University, Boston, USA; Pace University, New York City, USA; Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management at Narsee Monjee Institute of Management Studies (NMIMS), Mumbai, India; University of Geneva, Switzerland|
Launched in 2016, the Open Synthesis Network (OSN) is a collaborative project that aims to engage master’s and undergraduate students in research for neglected diseases. Read the Press Release
Currently the OSN has ten participating universities around the world: Imperial College London in the UK; Duke University, Northeastern University, Haverford College, Miami University, and Pace University in the USA; the NMIMS School of Pharmacy (Mumbai), Indian Institute of Technology (Gandhinagar), and the Indian Institute of Chemical Technology (Hyderabad) in India; and the University of Geneva in Switzerland. Students are working on compounds that kill leishmania donovani and leishmania infantum, the parasites that cause VL. DNDi’s current objective for VL is to discover compounds more suited for oral administration, easier to use in the field, and with fewer side effects than existing treatments. Any successful compounds that come from the OSN project will be evaluated further as part of DNDi’s discovery pipeline.
How the Open Synthesis Network works
Drugs for Neglected Diseases initiative will share data on existing compounds, from one of its active research projects, with university participants, along with a list of new, “wanted” chemical compounds. Students can then explore the existing data, understand the design rationale for the new compounds through open discussion with DNDi experts, and carry out the synthesis for one or more of these “wanted” compounds as part of their lab training. Students can use the data to design their own new compounds. DNDi will then test all new compounds for anti-parasitic activity, sharing the results openly with all OSN participants.
All work generated by OSN will be published in the public domain in real-time and remain free of intellectual property.
The online nature of OSN readily allows DNDi to open this collaboration to any universities interested in participating. To get involved, please contact Ben Perry: firstname.lastname@example.org